Pharmacology of cannabinoids
Keywords:
THC, CBD, Cannabinoids, Endocannabinoid receptorAbstract
Cannabinoids is a substance which has an effect on cannabinoid receptors. There were three types of cannabinoids. Endocannabinoid is an endogenous cannabinoid in human body. Phytocannabinoid is an extraction from Cannabis. Synthetic cannabinoid is a synthetic product which are derived from phytocannabinoid. Cannabinoids bind to both cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2) in a different binding affinity. The main effect of cannabinoid on CB1 is an inhibition of releasing neurotransmitters such as glutamate from pre-synaptic neuron. The biological effect of CB1 agonist has a potential therapeutic outcome in several pathological conditions, including chronic pain disorder and multiple sclerosis. Until present, Δ9-trans-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) are the most common phytocannabinoid that had been researching in clinical study.
References
Alsherbiny MA, Li CG. Medicinal Cannabis-Potential Drug Interactions. Medicines (Basel) 2018; 6(1).
Bosier B, Muccioli GG, Hermans E, Lambert DM. Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol 2010; 80:1-12.
Cascio MG, Marini P. Biosynthesis and Fate of Endocannabinoids. Handb Exp Pharmacol 2015; 231:39-58.
Cerne K. Toxicological properties of Delta9-tetrahydrocannabinol and cannabidiol. Arh Hig Rada Toksikol 2020; 71(1):1-11.
Cohen K, Weinstei AM. Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective. Front Public Health 2020; 6:1-8.
FDA and cannabis: Research and drug approval process [Internet]. [cited 11 Oct 2021]. Available from: https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process.
Hiley CR, Ford WR. Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. Biol Rev Camb Philos Soc 2004; 79:187-205.
Huestis MA . Humancannabinoid pharmacokinetics. Chem Biodivers 2007; 4:1770-804.
Iversen L. Cannabis and the brain. Brain 2003; 126:1252-70.
Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effect. Am Fam Physician 2007; 76:391-6.
McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manage 2005;10 (Suppl A):15A-22A.
McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and Delta(9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 2015; 172(3):737-53.
McPartland JM. Cannabis Systematics at the Levels of Family, Genus, and Species. Cannabis Cannabinoid Res 2018; 3(1):203-12.
Millar SA, Stone NL, Yates AS, O’Sullivan SE. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol 2018; 9:1365.
Ohlsson A, Lindgren J-E, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980; 409-16.
Pacher P, Batkai S, Kunos G. The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacol Rev 2006; 58:389–462.
Poyatos L, Perez-Acevedo AP, Papaseit E, Perez-Mana C, Martin S, Hladun O, et al. Oral Administration of Cannabis and Delta-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review. Medicina (Kaunas) 2020; 56(6):1-21.
Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry 1993; 163:141-9.
Wang R, Tu S, Zhang J, Shao A. Roles of TRP channels in neurological diseases. Oxid Med Cell Longev 2020; 2020:1-13.
WHO Expert Committee on Cannabidiol (CBD) Critical Review Report [Internet]. 2018 [cited 20 Aug 2021].
WHO Expert Committee on Drug Dependence Critical Review Delta-9-tetrahydrocannabinol [Internet]. 2018 [cited 20 Aug 2021]. Available from: https://www.who.int/medicines/access/controlled-substances/THCv1.pdf.
ตำรับยากัญชา โรงพยาบาลเจ้าพระยาอภัยภูเบศร [Internet]. [cited 11 Oct 2021]. Available from: https://cannabis.fda.moph.go.th/cpa/.
ตำรับยากัญชา องค์การเภสัชกรรม (GPO) [Internet]. [cited 11 Oct 2021]. Available from: https://cannabis.fda.moph.go.th/gpo/.
Downloads
Published
How to Cite
Issue
Section
License
ข้อความภายในบทความที่ตีพิมพ์ในวารสารสมาคมโรคหลอดเลือดสมองไทยเล่มนี้ ตลอดจนความรับผิดชอบด้านเนื้อหาและการตรวจร่างบทความเป็นของผู้นิพนธ์ ไม่เกี่ยวข้องกับกองบรรณาธิการแต่อย่างใด การนำเนื้อหา ข้อความหรือข้อคิดเห็นของบทความไปเผยแพร่ ต้องได้รับอนุญาตจากกองบรรณาธิการอย่างเป็นลายลักษณ์อักษร ผลงานที่ได้รับการตีพิมพ์ในวารสารเล่มนี้ถือเป็นลิขสิทธิ์ของวารสาร
